Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study
dc.contributor.author | Oruc, Zeynep | |
dc.contributor.author | Kaplan, Muhammet Ali | |
dc.contributor.author | Geredeli, Caglayan | |
dc.contributor.author | Sari, Nilgun Yildirim | |
dc.contributor.author | Ozaslan, Ersin | |
dc.contributor.author | Aytekin, Aydin | |
dc.contributor.author | Elkiran, Emin Tamer | |
dc.date.accessioned | 2024-04-24T17:37:35Z | |
dc.date.available | 2024-04-24T17:37:35Z | |
dc.date.issued | 2020 | |
dc.department | Dicle Üniversitesi | en_US |
dc.description.abstract | Purpose: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients. Methods: A total of 80 patients treated with eribulin in 12 medical oncology centers in Turkey between 2013-2017 were retrospectively evaluated. Sixteen potential prognostic variables were assessed for analysis. Results: The patients had received a median of 5 prior chemotherapy regimens and a median of 3 eribulin cycles for MBC. Median progression free survival (PFS) was 5.5 months (95% CI: 4.1-7.8) and median overall survival (OS) was 11 months (95 % CI: 6-15). Multivariate analysis showed that eribulin treatment line was shown to have independent prognostic significance for PFS. PFS difference was demostrated in patients who received 3 chemotherapy lines for advanced disease compared to those who had more than 3 chemotherapy lines [median PFS; 3 lines: 8.6 months (6.2-11) and >3 lines: 4.6 months (3.7-16) p=0.00]. The clinical benefit rate (CBR) was 52.5 and 35% in patients treated with three lines and with >3 previous chemotherapeutic regimens. Most common toxicities were neutropenia (62.5%), fatigue (52.5%), alopecia (50%) and nausea (37.5%). Conclusions: Eribulin treatment line was identified as indepedent prognostic factor for PFS in MBC patients. | en_US |
dc.identifier.endpage | 647 | en_US |
dc.identifier.issn | 1107-0625 | |
dc.identifier.issn | 2241-6293 | |
dc.identifier.issue | 2 | en_US |
dc.identifier.pmid | 32521847 | |
dc.identifier.scopus | 2-s2.0-85084634447 | |
dc.identifier.scopusquality | Q3 | |
dc.identifier.startpage | 641 | en_US |
dc.identifier.uri | https://hdl.handle.net/11468/21045 | |
dc.identifier.volume | 25 | en_US |
dc.identifier.wos | WOS:000549860000010 | |
dc.identifier.wosquality | Q4 | |
dc.indekslendigikaynak | Web of Science | |
dc.indekslendigikaynak | Scopus | |
dc.indekslendigikaynak | PubMed | |
dc.language.iso | en | en_US |
dc.publisher | Imprimatur Publications | en_US |
dc.relation.ispartof | Journal of Buon | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Metastatic Breast Cancer | en_US |
dc.subject | Eribulin | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Prognostic Factors | en_US |
dc.subject | Breast Cancer | en_US |
dc.title | Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study | en_US |
dc.title | Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study | |
dc.type | Article | en_US |